<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01718613</url>
  </required_header>
  <id_info>
    <org_study_id>NP 1079/17</org_study_id>
    <nct_id>NCT01718613</nct_id>
  </id_info>
  <brief_title>Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients</brief_title>
  <acronym>VANCS II</acronym>
  <official_title>Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <brief_summary>
    <textblock>
      Although arginine vasopressin has been used as an additional drug in refractory shock in
      worldwide clinical practice, there are no prospective studies using it as a first choice
      therapy in patients with cancer and septic shock.

      The aim of this study is assess if the use of arginine vasopressin would be more effective on
      treatment of septic shock in cancer patients than norepinephrine, decreasing the composite
      end point of mortality and organ failure in 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28-day from randomization</time_frame>
    <description>Mortality from all causes in 28-day follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90-days mortality</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Mortality from all causes 90 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of mechanical ventilation</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Days alive and free of mechanical ventilation at 28-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of vasopressors</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Days alive and free of any type of vasopressor agent at 28-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of renal replacement therapy</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>requirement of dialysis of hemofiltration at 28-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score in 24 hours</measure>
    <time_frame>24 hours after ICU admission</time_frame>
    <description>Severity of organ failure according to the Sequential Organ Failure Assessment (SOFA) score during the first 24 hours after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score in 96 hours</measure>
    <time_frame>96 hours after randomization</time_frame>
    <description>Severity of organ failure according to the Sequential Organ Failure Assessment (SOFA) score during the first 96 hours after randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement</description>
    <arm_group_label>Vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement</description>
    <arm_group_label>Norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid neoplasm needing ICU

          -  Septic Shock according standard criteria

        Exclusion Criteria:

          -  Younger than 18 years;

          -  Pregnancy;

          -  Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;

          -  Severe hyponatremia (Na&lt;130mEq/L);

          -  Acute mesenteric ischemia;

          -  Acute myocardial infarction;

          -  Cardiogenic shock;

          -  Current use of vasopressor before randomization

          -  Expected ICU stay less than 24 hours

          -  Enrolled in another study;

          -  Refusal to consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristiane M Zambolim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesia and Critical Care, Intensive Care Unit - ICESP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>Sao Paulo/SP</state>
        <zip>01246000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>October 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2012</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto do Cancer do Estado de São Paulo</investigator_affiliation>
    <investigator_full_name>Cristiane Maciel Zambolim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

